During the recent session, BioNexus Gene Lab Corp (NASDAQ:BGLC)’s traded shares were 0.44 million, with the beta value of the company hitting 1.85. At the last check today, the stock’s price was $4.75, reflecting an intraday gain of 22.42% or $0.87. The 52-week high for the BGLC share is $8.40, that puts it down -76.84 from that peak though still a striking 57.68% gain since the share price plummeted to a 52-week low of $2.01. The company’s market capitalization is $8.53M, and the average intraday trading volume over the past 10 days was 0.14 million shares, and the average trade volume was 655.25K shares over the past three months.

BioNexus Gene Lab Corp (NASDAQ:BGLC) trade information

BioNexus Gene Lab Corp (BGLC) registered a 22.42% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 22.42% in intraday trading to $4.75, hitting a weekly high. The stock’s 5-day price performance is 67.84%, and it has moved by 66.67% in 30 days. Based on these gigs, the overall price performance for the year is -8.64%. The short interest in BioNexus Gene Lab Corp (NASDAQ:BGLC) is 63611.0 shares and it means that shorts have 0.64 day(s) to cover.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -21.27%.

BGLC Dividends

BioNexus Gene Lab Corp is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

BioNexus Gene Lab Corp (NASDAQ:BGLC)’s Major holders

BioNexus Gene Lab Corp insiders own 51.11% of total outstanding shares while institutional holders control 0.88%, with the float percentage being 1.80%.

Also, the Mutual Funds coming in first place with the largest holdings of BioNexus Gene Lab Corp (BGLC) shares are Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund and Blackstone Alternative Investment Fd.s-Blackstone Alternative Multi-St . Data provided on Mar 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 23.68 shares. This amounts to just over 1.32 percent of the company’s overall shares, with a $0.12 million market value. The same data shows that the other fund manager holds slightly less at 3.0, or about 0.00% of the stock, which is worth about $14.0.